Patent Application
20160076048
The instant application includes a sequence listing in the form of a text file created 6 May 2011, named “506658035US00SeqList.txt” (63488 bytes) as well as submitted in the form of a paper copy, each of which is incorporated into the application by reference in its entirety.
The present teachings relate to monocot seeds and seed compositions containing levels of transferrin protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed, and methods of producing high levels of non-glycosylated transferrin protein in transgenic monocots, for use in making a serum-free cell culture medium, as well as animal, in particular human, therapeutic compositions.
Iron is an element used by eukaryotic organisms and most microorganisms as a cofactor of numerous proteins or enzymes for respiration, DNA synthesis, and many other critical metabolic processes (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003)). Cellular iron deficiency can arrest cell proliferation and even cause cell death, whereas the excessive iron will be toxic to cells by reacting with oxygen via the Fenton reaction to produce highly reactive hydroxyl radicals that cause oxidative damage to cells (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003); Hentze, M. U., et al., Cell 117: 285-97(2004)). To overcome the dual challenges of iron deficiency and overload, a family of iron carrier glycoproteins collectively called transferrins has evolved in nearly all organisms to tightly control cellular iron uptake, storage, and transport to maintain cellular iron homeostasis (Williams, J., Trends Biochem. Soc. 7: 394-397 (1982)). The transferrin protein family includes several homologous glycoproteins generally having a molecular weight of approximately 80 kDa and an ability to bind iron, and is divided into four subsets: (1) serum transferrins (TF) which have a role in iron transport in the body; (2) lactoferrins (LF) found in mammalian extracellular secretions such as milk, tears, pancreatic fluid and other bodily secretions of mammals; (3) melanotransferrins (mTF) which is present on the surface of melanocytes and in liver and intestinal epithelium; and (4) ovotransferrins (oTF) found in bird and reptile oviduct secretions and egg white. While all members of the transferrin protein family can bind iron to control free iron level, human serum transferrin provides both a means of transporting iron from the sites of absorption and storage to the sites of utilization, as well as protection against the damaging effects of iron-catalyzed free radicals. To date, only TF has been proven to be able to transport iron to cells (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003)).
One exemplary TF is a single-chain glycoprotein of 679 amino acid residues including 38 cysteine residues which are all disulfide bonded. TF consists of two homologous halves, each comprising about 340 amino acid residues and sharing about 40% sequence identity (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003); Hirose, Biosci. Biotechnol. Biochem. 64:1328-1336 (2000); J. Wally, et al., Biometals 20: 249-62 (2007)). The two homologous halves are shown by X-ray crystallography to fold into two distinct globular lobes called N- and C-terminal lobes (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003); Hirose, Biosci. Biotechnol. Biochem. 64:1328-1336 (2000)). Each lobe comprises two dissimilar domains (N1 and N2 in the N-lobe; C1 and C2 in the C-lobe) separated by a deep cleft, where the iron binding site is located. The iron-binding ligands in each lobe are identical, which involves the side chains of an aspartic acid, two tyrosines, a histidine and two oxygen molecules from a synergistic carbonate anion (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003); Hentze, M. U., et al., Cell 117: 285-97(2004); Hirose, Biosci. Biotechnol. Biochem. 64:1328-1336 (2000); J. Wally, et al., Biometals 20: 249-62 (2007); Q.-Y. He, et al., “Molecular aspects of release of iron from transferrin,” in: D. M. Templeton, (Ed.), Molecular and Cellular Iron Transport, CRC Press, 2002, pp. 95-124).
The cellular iron uptake and transport is normally driven by a TF/TF receptor (TFR)-mediated endocytotic process (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003)). When TF is free of iron (apo-TF), both its N- and C-lobes adopt an open conformation through keeping two domains in each lobe well separated for easy access of the ferric iron. At the extracellular pH of 7.4, the apo-TF binds one (monoferric TF) or two iron molecules (diferric TF or holo-TF) by the coordination of iron-binding ligands. The diferric TF then binds to TFR on the cell surface in a way that the TF C-lobe binds laterally at the helical domain of dimeric TFR while the TF N-lobe is sandwiched between the TFR ectodomain and the cell membrane (Cheng, et al., Cell 116: 565-76 (2004); Cheng, et al., J. Struct. Biol. 152: 204-210 (2005)). This TF-TFR complex is then endocytosed into the early endosome, where the acidic environment (pH 5.5) triggers the conformational change of TF-TFR and the subsequent release of iron from TF by first protonating and dissociating the synergistic anion followed by protonating iron binding-related His and/or Tyr ligands (Baker, et al., Proc Natl Acad Sci USA 100: 3579-3583 (2003); Q.-Y. He, et al., “Molecular aspects of release of iron from transferrin,” in: D. M. Templeton, (Ed.), Molecular and Cellular Iron Transport, CRC Press, 2002, pp. 95-124). Finally, the apo-TF-TFR complex is recycled to the cell surface, where the neutral extracellular pH will dissociate the complex and release the TF for re-use.
The TF-TFR complex-mediated endocytosis pathway for iron transport is not only biologically significant for maintaining cellular iron homeostasis, but also has important pharmaceutical applications. TF is also an important ingredient of serum-free cell culture media due to its role in regulating cellular iron uptake, transport, and utilization in cultured cells. TF in serum-free cell culture medium ensures iron delivery to propagating cells for sustained growth in mammalian culture for the production of therapeutic proteins and vaccines (Barnes, et al., Cell 22: 649-55 (1980); Laskey, et al., Exp. Cell Res. 176: 87-95 (1988); Mortellaro, et al., Biopharm. International 20 (Supp) 30-37 (2007); Sharath, et al., J Lab Clin Med 103: 739-48 (1984)).
In addition, TF has also been actively pursued as a drug-delivery vehicle. As a drug carrier, TF increases a drug's therapeutic index via its unique transferrin receptor-mediated endocytosis pathway, as well as its added advantages of being biodegradable, nontoxic, and nonimmunogenic (Qian, et al., Med. Res. Rev. 22: 225-50 (2002); Qian, et al. , Pharmacol. Rev. 54: 561-87 (2002); Soni, et al., American Journal of Drug Delivery 3: 155-70 (2005)). TF not only can deliver anti-cancer drugs to primary proliferating malignant cells where the TF is abundantly expressed (Qian, et al. , Pharmacol. Rev. 54: 561-87 (2002)), but also can deliver drugs to the brain by crossing the blood-brain barrier (BBB), which is a major barrier for administrating sufficient drugs to reach the central nervous system (CNS) (Qian, et al., Med. Res. Rev. 22: 225-50 (2002); Soni, et al., American Journal of Drug Delivery 3: 155-70 (2005); Pardridge, Discov. Med. 6:139-43(2006)). TF can also be exploited for oral delivery of protein-based therapeutics (Bai, et al., Proc. Natl. Acad. Sci. U.S.A. 102: 7292-6 (2005); Widera, et al., Adv. Drug Deliv. Rev. 55:1439-66(2003)), as TF is resistant to proteolytic degradation and TFR is abundantly expressed in human gastrointestinal (GI) epithelium (Bai, et al., Proc. Natl. Acad. Sci. U.S.A. 102: 7292-6 (2005); Banerjee, et al., Gastroenterology 91: 861-9 (1986)).
With the increasing concerns over the risk of transmission of infectious pathogenic agents from the use of human or animal plasma-derived TFs in both cell culture and drug delivery applications, recombinant transferrin (rTF) is preferred to native TF (Keenan, et al., Cytotechnology 51: 29-37(2006)). Recombinant human TF (rhTF) has long been pursued in a variety of expression systems (MacGillivray, et al., “Transferrins” in: D. M. Templeton, (Ed.), Molecular and cellular iron transport, Marcel Dekker, New York, 2002, pp. 41-70), but proves to be challenging largely due to hTF's complicated structural characteristics as described above. The commonly used E. coli system for production of recombinant proteins has proved to be impractical for producing rhTF, as the expressed rhTF protein remains in insoluble inclusion bodies and the yield of functionally active rhTF after renaturation is very limited (Hoefkens, et al., Int. J. Biochem. Cell Biol. 28: 975-82 (1996)). Although both the insect cell (baculovirus) (Ali, et al., Biochem. J. 319 (Pt 1):191-5 (1996)) and mammalian cell (MacGillivray, et al., “Transferrins” in: D. M. Templeton, (Ed.), Molecular and cellular iron transport, Marcel Dekker, New York, 2002, pp. 41-70) expression systems have been shown to be able to express the bioactive rhTF, neither of them express at high enough levels to provide enough quantity to be a feasible source of commercial production, as well as being cost prohibitive.
It is shown herein that when transferrin is expressed in bacterial, yeast, mammalian cells, and insect cell expression systems, the expressed native transferrin protein bears a glycosylation pattern characteristic of the host organism, i.e., animal cell-expressed transferrin has an animal-type glycosylation pattern, and yeast-expressed transferrin has a yeast-type glycosylation pattern. It is desirable to produce a biologically active transferrin protein that is non-glycosylated for therapeutic use, to avoid possible allergic or immunological reactivity. Recently, bioactive rhTF was expressed in Saccharomyces cerevisiae using a mutated transferrin gene in which two of its N-linked glycosylation sites have been knocked out, and this rhTF became commercially available. (Sargent, et al., BioMetals (2006) 19:513-519). However, this yeast-derived rhTF, still remains very expensive to produce (Millipore, Billerica, Mass.). To address the problems of the shortage and the high cost of producing rhTF, as well as to meet a previously unmet need for producing high levels of an non-glycosylated human transferrin, alternative expression systems are desirable.
With the advancement of plant molecular biology in general and the improvement of plant transformation techniques in particular, plant hosts have become a powerful system to produce recombinant proteins cost-effectively and on a large scale (Daniell, et al., Trends Plant Sci. 6: 219-26 (2001); Lienard, et al., Biotechnol. Annu. Rev. 13: 115-47 (2007); Twyman, et al., Expert Opin. Emerg. Drugs 10: 185-218 (2005); Huang, et al., “ExpressTec: high level expression of biopharmaceuticals in cereal grains” in: K. J, (Ed.), Modern Biopharmaceuticals, Wiley VCH, 2005, pp. 931-47).
None of the aforementioned patents or publications discloses the production of non-glycosylated native transferrin protein in monocot seeds in high yield. It is desirable to provide for the production of non-glycosylated native transferrin protein in high yield free from contaminating source agents in order to provide a sufficient supply of transferrin in serum-free cell culture medium as well as in therapeutic compositions for the patient population with conditions treatable by administration of transferrin protein.
Due to the high risk of contamination with blood-borne pathogens from the use of human- or animal plasma-derived transferrin, it is advantageous to produce recombinant transferrin from an alternative source, such as a crop plant, for use as a substitute for native human- or animal plasma-derived transferrin. Production of transferrin proteins in plants mitigates any possible contamination of the transferrin protein fraction by human or animal viruses and other disease causative agents found in human or animal plasma product fractions. In one aspect, the present disclosure provides expression of recombinant human transferrin (rhTF) in monocots, for example rice (Oryza sativa L.) grains, at high levels of expression, e.g., 1% seed dry weight (10 g/kg). The recombinant human transferrin was extracted with saline buffers and then purified by a one-step anion exchange chromatographic process to greater than 95% purity. The rice-derived recombinant human transferrin was biochemically and functionally characterized, and shown to be not only biochemically similar to the native human transferrin, but also functionally the same as native transferrin in terms of reversible iron binding and promoting cell growth and productivity. Specifically, the expressed rhTF was shown to be non-N-glycosylated by MALDI and PNGase F enzyme digestion analyses although the entire amino acid sequence of rhTF including its N-glycosylation sites had not been genetically modified to remove N-linked glycosylation sites. This monocot-derived rhTF was proved to be not only biochemically similar to the native hTF, but also functionally equivalent to the native hTF. Specifically, the monocot-derived rhTF reversibly bound iron and promoted cell growth and productivity. The ease of extraction and purification of recombinant hTF protein makes the present disclosure a viable system for commercial production of rhTF at high levels and low cost. Thus, the monocot-derived recombinant human transferrin described herein provides a safe and low cost alternative to human or animal plasma-derived transferrin for use in cell culture-based biopharmaceutical production of protein therapeutics and vaccines.
In one aspect, the disclosure provides a method of producing a recombinant non-glycosylated transferrin protein in monocot plant seeds, comprising the steps of:
(a) transforming a monocot plant cell with a chimeric gene comprising
(b) growing monocot plant from the transformed monocot plant cell for a time sufficient to produce seeds containing the transferrin protein; and
(c) harvesting the seeds from the plant, wherein the transferrin protein constitutes at least 0.1% seed weight of the harvested seeds.
In some embodiments, the transgenic monocot plant may further comprise a nucleic acid that encodes at least one transcription factor selected from the group consisting of O2 (encoded by the sequence set forth as SEQ ID NO: 20), PBF (encoded by the sequence set forth as SEQ ID NO: 21) and Reb (encoded by the sequence set forth as SEQ ID NO: 22).
The disclosure also provides a monocot plant seed-derived composition, selected from whole-seed food composition, a flour composition, an extract composition and a malt composition, prepared from the harvested seeds obtained by the disclosed method. In certain embodiments, the transferrin protein constitutes at least 1.0% of the dry weight the seed-derived composition.
The disclosure further provides a monocot seed-derived composition comprising an non-glycosylated transferrin protein, and at least one pharmaceutically acceptable excipient or nutrient, wherein the non-glycosylated transferrin protein is produced in a monocot plant containing a nucleic acid sequence encoding the transferrin protein and is extracted from seed harvested from the monocot plant. The excipient or nutrient is from a heterologous source other than the monocot plant. The formulation can be used for parenteral, enteric, inhalation, intranasal or topical delivery.
A serum-free cell culture medium comprising an extract of monocot seed expressing non-glycosylated transferrin protein and a method of making the serum-free cell culture medium are provided.
These and other objects and features of the claimed subject matter will become more fully apparent when the following detailed description is read in conjunction with the accompanying drawings and claims.
Several embodiments of the present disclosure are described in detail hereinafter. These embodiments may take many different forms and should not be construed as limited to those embodiments explicitly set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present disclosure to those skilled in the art.
As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “monocot plant” can mean, for example, a single monocot plant, such as a rice plant, or it can mean two or more of the same or different species of monocot plants.
As used herein, the following terms are intended to have the following meanings:
The term “stably transformed” with reference to a plant cell means the plant cell has a non-native (heterologous) nucleic acid sequence integrated into its genome which is maintained through two or more generations.
“Chimeric gene” or “heterologous nucleic acid construct,” as defined herein refers to a construct which has been introduced into a host and may include parts of different genes of exogenous or autologous origin, including regulatory elements. A chimeric gene construct for plant/seed transformation is typically composed of a transcriptional regulatory region (promoter) operably linked to a heterologous protein coding sequence, or, in a selectable marker heterologous nucleic acid construct, to a selectable marker gene encoding a protein conferring antibiotic resistance to transformed plant cells. A typical chimeric gene of the present disclosure, includes a transcriptional regulatory region inducible during seed development, a protein coding sequence, and a terminator sequence. A chimeric gene construct may also include a second DNA sequence encoding a signal peptide if secretion of the target protein is desired.
The term “gene” means the segment of DNA involved in producing a polypeptide chain, which may or may not include regions preceding and following the coding region, e.g. 5′ untranslated (5′ UTR) or “leader” sequences and 3′ UTR or “trailer” sequences, as well as intervening sequences (introns) between individual coding segments (exons).
The term “sequence identity” means nucleic acid or amino acid sequence identity in two or more aligned sequences, aligned using a sequence alignment program.
Exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, publicly available on the Internet at (ncbi.nlm.gov/BLAST/). See, also, Altschul, S. F. et al., 1990 and Altschul, S. F. et al., 1997.
The term “% homology” is used interchangeably herein with the term “% identity” and refers to the level of nucleic acid or amino acid sequence identity between two or more aligned sequences, when aligned using a sequence alignment program. For example, 70% homology means the same thing as 70% sequence identity determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 70% sequence identity over a length of the given sequence. Exemplary levels of sequence identity include, but are not limited to 70%, 75% 80%, 85%, 90% or 95% or more sequence identity to a given sequence, e.g., the coding sequence for transferrin, as described herein.
Sequence searches are typically carried out using the BLASTN program when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases. The BLASTX program is preferred for searching nucleic acid sequences which have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTN and BLASTX are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. (See ncbi.nlm.gov/BLAST/. See, also, Altschul, S. F. et al., 1990 and Altschul, S. F. et al., 1997).
A preferred alignment of selected sequences in order to determine “% identity” between two or more sequences, is performed using for example, the CLUSTAL-W program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.
A nucleic acid sequence is considered to be “selectively hybridizable” to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex or probe. For example, “maximum stringency” typically occurs at about Tm-5° C. (5° below the Tm of the probe); “high stringency” at about 5-10° below the Tm; “intermediate stringency” at about 10-20° below the Tm of the probe; and “low stringency” at about 20-25° below the Tm. Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while high stringency conditions are used to identify sequences having about 80% or more sequence identity with the probe.
Moderate and high stringency hybridization conditions are well known in the art (see, for example, Sambrook et al, 1989, Chapters 9 and 11, and in Ausubel et al., 1993, expressly incorporated by reference herein). An example of high stringency conditions includes hybridization at about 42° C. in 50% formamide, 5×SSC, 5×Denhardt's solution, 0.5% SDS and 100 μg/ml denatured carrier DNA followed by washing two times in 2×SSC and 0.5% SDS at room temperature and two additional times in 0.1×SSC and 0.5% SDS at 42° C.
“Heterologous DNA” refers to DNA which has been introduced into plant cells from another source, or which can be from a plant source, including the same plant source, but which is under the control of a promoter that does not normally regulate expression of the heterologous DNA.
“Heterologous protein” is a protein encoded by a heterologous DNA.
As used herein, “recombinant” includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid sequence or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all as a result of deliberate human intervention.
A plant cell, tissue, organ, or plant into which a heterologous nucleic acid construct comprising the coding sequence for an anti-microbial protein or peptide has been introduced is considered transformed, transfected, or transgenic. A transgenic or transformed cell or plant also includes progeny of the cell or plant and progeny produced from a breeding program employing such a transgenic plant as a parent in a cross and exhibiting an altered phenotype resulting from the presence of the coding sequence for an anti-microbial protein. Hence, a plant of the present disclosure will include any plant which has a cell containing introduced nucleic acid sequences, regardless of whether the sequence was introduced into the plant directly through transformation means or introduced by generational transfer from a progenitor cell which originally received the construct by direct transformation.
The term “transgenic plant” refers to a plant that has incorporated exogenous nucleic acid sequences, i.e., nucleic acid sequences which are not present in the native (“untransformed”) plant or plant cell. Thus a plant having within its cells a heterologous polynucleotide is referred to herein as a “transgenic plant.” The heterologous polynucleotide can be either stably integrated into the genome, or can be extra-chromosomal. The polynucleotide of the present disclosure may be stably integrated into the genome such that the polynucleotide is passed on to successive generations. The term “transgenic” as used herein does not encompass the alteration of the genome (chromosomal or extra-chromosomal) by conventional plant breeding methods or by naturally occurring events such as random cross-fertilization, non-recombinant viral infection, non-recombinant bacterial transformation, non-recombinant transposition, or spontaneous mutation. “Transgenic” is used herein to include any cell, cell line, callus, tissue, plant part or plant, the genotype of which has been altered by the presence of heterologous nucleic acids including those transgenics initially so altered as well as those created by sexual crosses or asexual reproduction of the initial transgenics.
The terms “transformed,” “stably transformed” or “transgenic” with reference to a plant cell means the plant cell has a non-native (heterologous) nucleic acid sequence integrated into its genome which is maintained through two or more generations.
The term “expression” with respect to a protein or peptide refers to the process by which the protein or peptide is produced based on the nucleic acid sequence of a gene. The process includes both transcription and translation. The term “expression” may also be used with respect to the generation of RNA from a DNA sequence.
The term “introduced” in the context of inserting a nucleic acid sequence into a cell, means “transfection,” or “transformation” or “transduction” and includes the incorporation of a nucleic acid sequence into a eukaryotic or prokaryotic cell where the nucleic acid sequence may be incorporated into the genome of the cell (for example, chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (for example, transfected mRNA).
By “host cell” is meant a cell containing a vector and supporting the replication and/or transcription and/or expression of the heterologous nucleic acid sequence.
A “plant cell” refers to any cell derived from a plant, including undifferentiated tissue (e.g., callus) as well as plant seeds, pollen, propagules, embryos, suspension cultures, meristematic regions, leaves, roots, shoots, gametophytes, sporophytes and microspores.
The term “mature plant” refers to a fully differentiated plant.
The term “seed product” includes, but is not limited to, seed fractions such as de-hulled whole seed, a flour composition (seed that has been de-hulled by milling and ground into a powder) a seed extract composition, in some embodiments, a protein extract (where the protein fraction of the flour has been separated from the carbohydrate fraction), a malt composition (including malt extract or malt syrup) and/or a purified protein fraction derived from the transgenic grain.
The term “biological activity” refers to any biological activity typically attributed to that protein by those of skill in the art.
The term “non-nutritional” refers to a pharmaceutically acceptable excipient which does not as its primary effect provide nutrition to the recipient. The excipient may provide one of the following services to an enterically delivered formulation, including acting as a carrier for a therapeutic protein, protecting the protein from acids in the digestive tract, providing a time-release of the active ingredients being delivered, or otherwise providing a useful quality to the formulation in order to administer to the patient the transferrin protein.
“Monocot seed components” refers to carbohydrate, protein, and lipid components extractable from monocot seeds, typically mature monocot seeds.
“Seed maturation” refers to the period starting with fertilization in which metabolizable reserves, e.g., sugars, oligosaccharides, starch, phenolics, amino acids, and proteins, are deposited, with and without vacuole targeting, to various tissues in the seed (grain), e.g., endosperm, testa, aleurone layer, and scutellar epithelium, leading to grain enlargement, grain filling, and ending with grain desiccation.
“Maturation-specific protein promoter” refers to a promoter exhibiting substantially upregulated activity (greater than 25%) during seed maturation.
A “signal sequence” is an N- or C-terminal polypeptide sequence which is effective to localize the peptide or protein to which it is attached to a selected intracellular or extracellular region. In some embodiments, the signal sequence targets the attached peptide or protein to a location such as an endosperm cell, in certain embodiments, an endosperm-cell organelle, such as an intracellular vacuole or other protein storage body, chloroplast, mitochondria, or endoplasmic reticulum, or extracellular space, following secretion from the host cell.
“Transferrin” can refer to a transferrin protein or protein-encoding sequence from an animal, such as a mammal, including a human. Exemplary amino acid sequences for mammalian transferrins are disclosed herein as the mature human transferrin protein Swiss-Prot accession number P02787, (identified herein as SEQ ID NO: 3); murine transferrin protein GenBank accession AAL34533.1 (identified herein as SEQ ID NO: 24); rat transferrin protein GenBank accession BAA07458.1 (identified herein as SEQ ID NO: 25); porcine transferrin protein GenBank accession CAQ34904.1 (identified herein as SEQ ID NO: 26); and macaque transferrin protein GenBank accession ACB11584.1 (identified herein as SEQ ID NO: 27).
“Non-glycosylated” or “unglycosylated” means without observable N-linked glycosylation, within the limits of detection by isoelectric focusing, PNGase F digestion and/or MALDI analysis. These terms make no reference to or implications about the O-linked glycosylation status of a protein.
“Native transferrin” means transferrin protein that is not produced from a mutated recombinant gene.
“Plant-derived” means that the source of the ingredient is a plant.
“Dry weight percent” or “% dry weight” or “percent seed dry weight” means, for example, a protein-yield of grams transferrin per kilogram of dry seeds. For example, 1% seed dry weight of rice-expressed transferrin means that 1 kilogram of rice grains yields 10 grams of transferrin protein.
“Total protein” and “total soluble protein” are used interchangeably, unless otherwise specified. Thus, unless otherwise noted, any given weight of total protein measured should be interpreted by the skilled artisan to mean total soluble protein. Further, a value given in μg/mg TSP to the corresponding value given in % TSP. As an example, 1 μg/1 mg TSP is equivalent to 1 μg per 1000 μg TSP (or 0.001 μg/μg TSP) which, expressed as a percentage of TSP in μg weight, would be 0.1% TSP measured in μg. For example, 30.3 μg/mg total (soluble) protein. This translates to 0.0303 μg per μg TSP, which, stated as a percentage, equals 3.03% TSP.
Units can also be expressed as μg per grain of monocot seed. This weight can be correlated with the percentage of total soluble protein, given that the average weight of a seed/grain and how much of this weight is represented by the TSP are matters readily known to skilled artisans. For example, the 1000 grain weight of rice is, on average, approximately 20-25 grams, which translates to 20-25 mg (or 20,000-25,000 μg) per rice grain. As one example, a transgenic rice plant may typically yield 190 μg total soluble protein per grain which is roughly equivalent to 0.8% grain weight (190 μg divided by 25,000 μg=0.0076 which is rounded up to 0.8%).
As is known in the art, “endosperm” or “endosperm tissue” is a seed storage tissue found in mature seeds.
The terms “crude extract,” “partially-purified” or “substantially unpurified” means that a composition made from the transgenic monocot seed is not subjected to significant purification steps, such as chromatographic protein purification and fractionation steps.
In some embodiments, the host cell is a monocot plant cell, such as, for example, a monocot endosperm cell. Other host cells may be used as secondary hosts, including bacterial, yeast, insect, amphibian or mammalian cells, to move DNA to a desired plant host cell.
The polynucleotides of the disclosure may be in the form of RNA or in the form of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and genomic DNA The DNA may be double-stranded or single-stranded, and if single-stranded may be the coding strand or the non-coding (antisense, complementary) strand.
Expression vectors for use in the present disclosure are chimeric nucleic acid constructs (or expression vectors or cassettes), designed for operation in plants, with associated upstream and downstream sequences.
In general, expression vectors can include the following operably linked components that constitute a chimeric gene: a promoter from the gene of a maturation-specific monocot plant storage protein, a first DNA sequence, operably linked to the promoter, encoding a monocot plant seed-specific signal sequence (such as an N-terminal leader sequence or a C-terminal trailer sequence) capable of targeting a polypeptide linked thereto to an endosperm cell, in some embodiments an endosperm-cell organelle, such as a protein storage body, and a second DNA sequence, linked in translation frame with the first DNA sequence, encoding a transferrin protein. The signal sequence may be cleaved from the transferrin protein in the plant cell.
An exemplary DNA sequence encoding native human transferrin is set forth as SEQ ID NO: 1. An exemplary codon-optimized DNA sequence encoding human transferrin is set forth as SEQ ID NO: 2.
The chimeric gene, in turn, is typically placed in a suitable plant-transformation vector having (i) companion sequences upstream and/or downstream of the chimeric gene which are of plasmid or viral origin and provide necessary characteristics to the vector to permit the vector to move DNA from bacteria to the desired plant host; (ii) a selectable marker sequence; and (iii) a transcriptional termination region generally at the opposite end of the vector from the transcription initiation regulatory region.
Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of plant host cells. The promoter region is chosen to be regulated in a manner allowing for induction under seed-maturation conditions. In one aspect, the expression construct includes a promoter which exhibits specifically upregulated activity during seed maturation. Promoters are typically derived from cereals such as rice, barley, wheat, oat, rye, corn, millet, triticale or sorghum. Examples of such promoters include the maturation-specific promoter region associated with one of the following maturation-specific monocot plant storage proteins: rice glutelins, oryzins, and prolamines, barley hordeins, wheat gliadins and glutelins, maize zeins and glutelins, oat glutelins, and sorghum kafirins, millet pennisetins, and rye secalins. Exemplary regulatory regions from these genes are exemplified by SEQ ID NOS: 4-12. Some promoters suitable for expression in maturing seeds include the barley endosperm-specific B1-hordein promoter, GluB-2 promoter, Bx7 promoter, Gt3 promoter, GluB-1 promoter and Rp-6 promoter, particularly if these promoters are used in conjunction with transcription factors.
“Alpha-amylase” as used herein refers to an enzyme which principally breaks starch into dextrins. “Beta-amylase” as used herein refers to an enzyme which converts start and dextrins into maltose. An exemplary coding sequence of the rice alpha-amylase (RAmy3D) gene is set forth in GenBank accession M59351.1 (identified herein as SEQ ID NO: 28). See Huang, et al., Nucleic Acids Res. 18 (23), 7007-7014 (1990).
Of particular interest is the expression of the nucleic acid encoding a transferrin protein from a promoter that is preferentially expressed in plant seed tissue. Examples of such promoter sequences include those sequences derived from sequences encoding plant storage protein genes or from genes involved in fatty acid biosynthesis in oilseeds. Exemplary promoters include a glutelin (Gt1) promoter, which effects gene expression in the outer layer of the endosperm, and a globulin (Glb) promoter, which effects gene expression in the center of the endosperm. Promoter sequences for regulating transcription of gene coding sequences operably linked thereto include naturally-occurring promoters, or regions thereof capable of directing seed-specific transcription, and hybrid promoters, which combine elements of more than one promoter. Methods for construction such hybrid promoters are well known in the art.
In some cases, the promoter is native to the same plant species as the plant cells into which the chimeric nucleic acid construct is to be introduced. In other embodiments, the promoter is heterologous to the plant host cell.
Alternatively, a seed-specific promoter from one type of monocot may be used regulate transcription of a nucleic acid coding sequence from a different monocot or a non-cereal monocot.
In addition to encoding the protein of interest, the expression cassette or heterologous nucleic acid construct includes DNA encoding a signal peptide that allows processing and translocation of the protein, as appropriate. Exemplary signal sequences are those sequences associated with the monocot maturation-specific genes: glutelins, prolamines, hordeins, gliadins, glutenins, zeins, albumin, globulin, AOP glucose pyrophosphorylase, starch synthase, branching enzyme, Em, and lea. Exemplary sequences encoding a signal peptide for a protein storage body are identified herein as SEQ ID NOS:13-19.
In one embodiment, the method is directed toward the localization of proteins in an endosperm cell, in some embodiments an endosperm-cell organelle, such as a protein storage body, mitochondrion, endoplasmic reticulum, vacuole, chloroplast or other plastidic compartment. For example, when proteins are targeted to plastids, such as chloroplasts, in order for expression to take place the construct also employs the use of sequences to direct the gene product to the plastid, Such sequences are referred to herein as chloroplast transit peptides (CTP) or plastid transit peptides (PTP). In this manner, when the gene of interest is not directly inserted into the plastid, the expression construct additionally contains a gene encoding a transit peptide to direct the gene of interest to the plastid. The chloroplast transit peptides may be derived from the gene of interest, or may be derived from a heterologous sequence having a CTP. Such transit peptides are known in the art. (See, for example, Von Heijne et al., 1991 Plant Mol. Biol. Rep., 9:104-126; and U.S. Pat. Nos. 4,940,835 and 5,728,925). Additional transit peptides for the translocation of the protein to the endoplasmic reticulum (ER) (Chrispeels K., Ann. Rev. Plant Phys. Plant Mol. Biol., 42:21-53, 1991), nuclear localization signals (Shieh et al., Plant Physiol. 1993 February; 101(2): 353-361; Varagona et al., Plant Cell 1992 October; 4(10): 1213-1227) or vacuole (Raikhel N., Plant Phys., 100:1627-1632, 1992; and U.S. Pat. No. 5,360,726) may also find use in the constructs of the present disclosure.
Another exemplary class of signal/targeting/transport sequences are sequences effective to promote secretion of heterologous protein from aleurone cells during seed germination, including the signal sequences associated with alpha-amylase, protease, carboxypeptidase, endoprotease, ribonuclease, DNase/RNase, (1-3)-beta-glucanase, (1-3)(1-4)-beta-glucanase, esterase, acid phosphatase, pentosamine, endoxylanase, β-xylopyranosidase, arabinofuranosidase, beta-glucosidase, (1-6)-beta-glucanase, perioxidase, and lysophospholipase.
Since many protein storage proteins are under the control of a maturation-specific promoter, and this promoter is operably linked to a signal sequence for targeting to a protein body, the promoter and signal sequence can be isolated from a single protein-storage gene, then operably linked to a transferrin protein in the chimeric gene construction. One exemplary promoter-signal sequence combination is exemplified in the sequence identified by SEQ ID NO:4, in which the promoter and signal sequence both come from the rice Gt1 gene regulatory region. Alternatively, the promoter and leader sequence may be derived from different genes. One exemplary promoter-signal sequence combination is the rice Glb promoter linked to the rice Gt1 leader sequence (SEQ ID NO:5).
Expression vectors or heterologous nucleic acid constructs designed for operation in plants comprise companion sequences upstream and downstream to the expression cassette. The companion sequences are of plasmid or viral origin and provide necessary characteristics to the vector to permit the vector to move DNA from a secondary host to the plant host, such as, sequences containing an origin of replication and a selectable marker. Typical secondary hosts include bacteria and yeast.
In one embodiment, the secondary host is E. coli, the origin of replication is a CoIE1-type, and the selectable marker is a gene encoding ampicillin resistance. Such sequences are well known in the art and are commercially available as well (e.g., Clontech, Palo Alto, Calif.; Stratagene, La Jolla, Calif.
The transcription termination region may be taken from a gene where it is normally associated with the transcriptional initiation region or may be taken from a different gene. Exemplary transcriptional termination regions include the NOS terminator from Agrobacterium Ti plasmid and the rice α-amylase terminator.
Polyadenylation tails may also be added to the expression cassette to optimize high levels of transcription and proper transcription termination, respectively. Polyadenylation sequences include, but are not limited to, the Agrobacterium octopine synthetase signal, or the nopaline synthase of the same species.
Suitable selectable markers for selection in plant cells include, but are not limited to, antibiotic resistance genes, such as, kanamycin (nptll), G418, bleomycin, hygromycin, chloramphenicol, ampicillin, tetracycline, and the like. Additional selectable markers include a bar gene which codes for bialaphos resistance; a mutant EPSP synthase gene which encodes glyphosate resistance; a nitrilase gene which confers resistance to bromoxynil; a mutant acetolactate synthase gene (ALS) which confers imidazolinone or sulphonylurea resistance; and a methotrexate resistant DHFR gene.
The particular marker gene employed is one which allows for selection of transformed cells as compared to cells lacking the DNA which has been introduced. The selectable marker gene is one which facilitates selection at the tissue culture stage, e.g., a kanamyacin, hygromycin or ampicillin resistance gene.
The vectors of the present disclosure may also be modified to include intermediate plant transformation plasmids that contain a region of homology to an Agrobacterium tumefaciens vector, a T-DNA border region from Agrobacterium tumefaciens, and chimeric genes or expression cassettes (described above). Further, the vectors may comprise a disarmed plant tumor inducing plasmid of Agrobacterium tumefaciens.
In general, a selected nucleic acid sequence is inserted into an appropriate restriction endonuclease site or sites in the vector. Standard methods for cutting, ligating and transformation into a secondary host cell, known to those of skill in the art, are used in constructing vectors for use in the present disclosure. (See generally, Maniatis et al. Molecular Cloning: A Laboratory Manual, 2nd Edition, 1989; Ausubel et al. Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1993; and Gelvin et al., eds. Plant Molecular Biology Manual, 1990).
Plant cells or tissues are transformed with expression constructs (heterologous nucleic acid constructs, e.g., plasmid DNA into which the gene of interest has been inserted) using a variety of standard techniques. Effective introduction of vectors in order to facilitate enhanced plant gene expression is an important aspect of the disclosure. The vector sequences may be stably transformed, and may be integrated into the host genome.
The method used for transformation of host plant cells is not critical to the present disclosure. The skilled artisan will recognize that a wide variety of transformation techniques exist in the art, and new techniques are continually becoming available. Any technique that is suitable for the target host plant may be employed within the scope of the present disclosure. For example, the constructs can be introduced in a variety of forms including, but not limited to, as a strand of DNA, in a plasmid, or in an artificial chromosome. The introduction of the constructs into the target plant cells can be accomplished by a variety of techniques, including, but not limited to calcium-phosphate-DNA co-precipitation, electroporation, microinjection, Agrobacterium-mediated transformation, liposome-mediated transformation, protoplast fusion or microprojectile bombardment (Christou, 1992; Sanford et al., 1993). The skilled artisan can refer to the literature for details and select suitable techniques for use in the presently disclosed.
When Agrobacterium is used for plant cell transformation, a vector is introduced into the Agrobacterium host for homologous recombination with T-DNA or the Ti- or Ri-plasmid present in the Agrobacterium host The Ti- or Ri-plasmid containing the T-DNA for recombination may be armed (capable of causing gall formation) or disarmed (incapable of causing gall formation), the latter being permissible, so long as the vir genes are present in the transformed Agrobacterium host The armed plasmid can give a mixture of normal plant cells and gall.
In some instances where Agrobacterium is used as the vehicle for transforming host plant cells, the expression or transcription construct bordered by the T-DNA border region(s) is inserted into a broad host range vector capable of replication in E. coli and Agrobacterium, examples of which are described in the literature, for example pRK2 or derivatives thereof. See, for example, Ditta et al., 1980 and EPA 0 120 515. Alternatively, one may insert the sequences to be expressed in plant cells into a vector containing separate replication sequences, one of which stabilizes the vector in E. coli, and the other in Agrobacterium. See, for example, McBride and Summerfeit 1990, wherein the pRiHRI (Jouanin, et al., 1985), origin of replication is utilized and provides for added stability of the plant expression vectors in host Agrobacterium cells.
Included with the expression construct and the T-DNA is one or more selectable marker coding sequences which allow for selection of transformed Agrobacterium and transformed plant cells. A number of antibiotic resistance markers have been developed for use with plant cells, these include genes inactivating antibiotics such as kanamycin, the aminoglycoside G418, hygromycin, or the like. The particular marker employed is not essential to this disclosure, with a particular marker preferred depending on the particular host and the manner of construction.
For Agrobacterium-mediated transformation of plant cells, explants are incubated with Agrobacterium for a time sufficient to result in infection, the bacteria killed, and the plant cells cultured in an appropriate selection medium. Once callus forms, shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish repetitive generations and for isolation of the recombinant protein produced by the plants.
There are a number of possible ways to obtain plant cells containing more than one expression construct. In one approach, plant cells are co-transformed with a first and second construct by inclusion of both expression constructs in a single transformation vector or by using separate vectors, one of which expresses desired genes. The second construct can be introduced into a plant that has already been transformed with the first expression construct, or alternatively, transformed plants, one having the first construct and one having the second construct, can be crossed to bring the constructs together in the same plant.
In one embodiment, the plants used in the methods of the present disclosure are derived from members of the taxonomic family known as the Gramineae. This includes all members of the grass family of which the edible varieties are known as cereals. The cereals include a wide variety of species such as wheat (Triticum sps.), rice (Oryza sps.) barley (Hordeum sps.) oats, (Avena sps.) rye (Secale sps.), corn (maize) (Zea sps.) and millet (Pennisettum sps.). In practicing the present disclosure, exemplary grains are rice, wheat, maize, barley, rye and triticale.
In order to produce transgenic plants that express transferrin protein in seeds, monocot plant cells or tissues derived from them are transformed with an expression vector comprising the coding sequence for a transferrin protein. The transgenic plant cells are cultured in medium containing the appropriate selection agent to identify and select for plant cells which express the heterologous nucleic acid sequence. After plant cells that express the heterologous nucleic acid sequence are selected, whole plants are regenerated from the selected transgenic plant cells. Techniques for regenerating whole plants from transformed plant cells are generally known in the art Transgenic plant lines, e.g., rice, wheat, corn or barely, can be developed and genetic crosses carried out using conventional plant breeding techniques.
Transformed plant cells are screened for the ability to be cultured in selective media having a threshold concentration of a selective agent. Plant cells that grow on or in the selective media are typically transferred to a fresh supply of the same media and cultured again. The explants are then cultured under regeneration conditions to produce regenerated plant shoots. After shoots form, the shoots are transferred to a selective rooting medium to provide a complete plantlet. The plantlet may then be grown to provide seed, cuttings, or the like for propagating the transformed plants. The method provides for efficient transformation of plant cells and regeneration of transgenic plants, which can produce a recombinant transferrin protein.
The expression of the recombinant transferrin protein may be confirmed using standard analytical techniques such as Western blot, ELISA, PCR, HPLC, NMR, or mass spectroscopy, together with assays for a biological activity specific to the particular protein being expressed.
A purified transferrin protein recombinantly produced in a plant cell, in some embodiments mostly free of contaminants of the host plant cell is also provided. In some embodiments, the presence or absence of plant glycosyl groups can indicate that the transferrin protein was produced in a plant, but does not significantly impair the biological activity of the transferrin protein in any of the applied therapeutic contexts (such that, for example, the recombinant TG has less than a 25% loss of activity or less than 10% loss of activity, as compared to a corresponding non-recombinant transferrin protein). Typically, in accordance with some embodiments, the transferrin protein constitutes at least about 0.1%, at least about 0.5%, at least about 1.0% or at least about 2.0% of the total soluble protein (TSP) in the seeds harvested from the transgenic plant. In some embodiments, however, protein expression is much higher than previously reported, i.e., at least about 3.0%, which makes commercial production quite feasible. Advantageously, protein expression is at least about 5.0%, at least about 10%, at least about 15%, at least about 20%, at least about 30%, or even at least about 40% of total soluble protein.
A plant seed product prepared from the harvested seeds is also provided in the present disclosure. Preferably, the transferrin protein constitutes at least about 3.0% of the total soluble protein in the seed product, more preferably at least about 5.0%, and most preferably at least about 10.0%. As shown in the figures, the expression of transferrin proteins in rice grains, represented by AAT, the three fibrinogen polypeptides and HSA represent at least about 10% of total soluble protein.
The present disclosure also provides compositions comprising transferrin proteins produced recombinantly in the seeds of monocot plants, and methods of making such compositions.
In practicing the disclosed method, a transferrin protein is produced in the seeds or grain of transgenic plants that express the nucleic acid coding sequence for the transferrin protein. After expression, the transferrin protein may be provided to a patient in substantially unpurified form (i.e., at least 10-20% of the composition comprises plant material), or the transferrin protein may be isolated or purified from a product of the mature seed (e.g., a flour, extract, malt or whole seed composition, etc.) and formulated for delivery to a patient.
Such compositions can comprise a formulation for the type of delivery intended. Delivery types can include, e.g. parenteral, enteric, inhalation, intranasal or topical delivery. Parenteral delivery can include, e.g. intravenous, intramuscular, or suppository. Enteric delivery can include, e.g. oral administration of a pill, capsule, or other formulation made with a non-nutritional pharmaceutically-acceptable excipient, or a composition with a nutrient from the transgenic plant, for example, in the grain extract in which the protein is made, or from a source other than the transgenic plant. Such nutrients include, for example, salts, saccharides, vitamins, minerals, amino acids, peptides, and proteins other than the transferrin protein. Intranasal and inhalant delivery systems can include spray or aerosol in the nostrils or mouth. Topical delivery can include, e.g. creams, topical sprays, or salves. Preferably, the composition is substantially free of contaminants of the transgenic plant, preferably containing less than 20% plant material, more preferably less than 10%, and most preferably, less than 5%. The preferable route of administration is enteric, and preferably the composition is non-nutritional.
The transferrin protein can be purified from the seed product by a mode including grinding, filtration, heat, pressure, salt extraction, evaporation, or chromatography.
The transferrin proteins produced in accordance with the disclosure also include all variants thereof, whether allelic variants or synthetic variants. A “variant” transferrin protein-encoding nucleic acid sequence may encode a variant transferrin protein amino acid sequence that is altered by one or more amino acids from the native transferrin protein sequence, preferably at least one amino acid substitution, deletion or insertion. The nucleic acid substitution, insertion or deletion leading to the variant may occur at any residue within the sequence, as long as the encoded amino acid sequence maintains substantially the same biological activity of the native transferrin protein. In another embodiment, the variant transferrin protein nucleic acid sequence may encode the same polypeptide as the native sequence but, due to the degeneracy of the genetic code, the variant has a nucleic acid sequence altered by one or more bases from the native polynucleotide sequence.
The variant nucleic acid sequence may encode a variant amino acid sequence that contains a “conservative” substitution, wherein the substituted amino acid has structural or chemical properties similar to the amino acid which it replaces and physicochemical amino acid side chain properties and high substitution frequencies in homologous proteins found in nature (as determined, e.g., by a standard Dayhoff frequency exchange matrix or BLOSUM matrix). In addition, or alternatively, the variant nucleic acid sequence may encode a variant amino acid sequence containing a “non-conservative” substitution, wherein the substituted amino acid has dissimilar structural or chemical properties to the amino acid it replaces. Standard substitution classes include six classes of amino acids based on common side chain properties and highest frequency of substitution in homologous proteins in nature, as is generally known to those of skill in the art and may be employed to develop variant transferrin protein-encoding nucleic acid sequences.
A transferrin protein-encoding nucleotide sequence may be engineered in order to alter the transferrin protein coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the transferrin protein by a cell.
As will be understood by those of skill in the art, in some cases it may be advantageous to use a transferrin protein-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular eukaryotic host can be selected, for example, to increase the rate of transferrin protein expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence. As an example, it has been shown that codons for genes expressed in rice are rich in guanine (G) or cytosine (C) in the third codon position (Huang et al., 1990). Changing low G+C content to a high G+C content has been found to increase the expression levels of foreign protein genes in barley grains (Horvath et al., 2000). The transferrin protein encoding genes can be synthesized by Operon Technologies (Alameda, Calif. based on the rice gene codon bias (Huang et al., 1990) along with the appropriate restriction sites for gene cloning. These ‘codon-optimized’ genes are then linked to regulatory/secretion sequences for seed-directed monocot expression and these chimeric genes then inserted into the appropriate plant transformation vectors.
Heterologous nucleic acid constructs may include the coding sequence for a transferrin protein (i) in isolation; (ii) in combination with additional coding sequences; such as fusion protein or signal peptide, in which the transferrin protein coding sequence is the dominant coding sequence; (iii) in combination with non-coding sequences, such as introns and control elements, such as promoter and terminator elements or 5′ and/or 3′ untranslated regions, effective for expression of the coding sequence in a suitable host; and/or (iv) in a vector or host environment in which the transferrin protein coding sequence is a heterologous gene.
Depending upon the intended use, an expression construct may contain the nucleic acid sequence encoding the entire transferrin protein, or a portion thereof. For example, where transferrin protein sequences are used in constructs for use as a probe, it may be advantageous to prepare constructs containing only a particular portion of the transferrin protein encoding sequence, for example a sequence which is discovered to encode a highly conserved transferrin protein region.
In some embodiments, a seed composition containing a flour, extract, or malt obtained from mature monocot seeds and one or more seed-produced transferrin proteins in unpurified form is provided. Isolating the transferrin proteins from the flour can entail forming an extract composition by milling seeds to form a flour, extracting the flour with an aqueous buffered solution, and optionally, further treating the extract to partially concentrate the extract and/or remove unwanted components. In a preferred method, mature monocot seeds, such as rice seeds, are milled to a flour, and the flour then suspended in saline or in a buffer, such as Phosphate Buffered Saline (“PBS”), ammonium bicarbonate buffer, ammonium acetate buffer or Tris buffer. A volatile buffer or salt, such as ammonium bicarbonate or ammonium acetate may obviate the need for a salt-removing step, and thus simplify the extract processing method.
In some embodiments, the level of protein expressed in a transgenic plant is assessed from a crude extract or substantially unpurified composition from the plant seed. In some embodiments, a grain or milled grain or flour composition, an extract composition, or malt composition obtained from mature monocot seeds is produced in substantially unpurified form. The transferrin protein may be present in an amount between about 0.05 and 0.5 grams protein/kg total soluble protein. For a grain composition, the level of transferrin protein present may be between 0.1 to 1% of total seed weight. For an extract composition, the transferrin protein may be concentrated to form up to 5-40% or more of the total extract weight. A malt composition, which will contain a significant percent of malt sugars, in addition to native proteins as well as heterologous transferrin protein, will typically contain an amount of protein that is intermediate between that of grain and the extract.
The flour suspension is incubated with shaking for a period typically between 30 minutes and 4 hours, at a temperature between 20-55° C., The resulting homogenate is clarified either by filtration or centrifugation. The clarified filtrate or supernatant may be further processed, for example by ultrafiltration or dialysis or both to remove contaminants such as lipids, sugars and salt. Finally, the material maybe dried, e.g., by lyophilization, to form a dry cake or powder. The extract combines advantages of high protein yields, essentially limiting losses associated with protein purification,
In general, the protein once produced in a product of a mature seed can be further purified by standard methods known in the art, such as by filtration, affinity column, gel electrophoresis, and other such standard procedures. The purified protein can then be formulated as desired for delivery to a human patient. More than one protein can be combined for the therapeutic formulation. The protein may be purified and used in biomedical applications requiring a non-food administration of the protein.
Illustrative publications describing components of precursor compositions, as well as methods for preparing certain compositions include the following: U.S. patent Ser. Nos. 12/751,869 and 12/558,189; U.S. Patent Application Publication Nos. 20080318277; 20090156486; 20090258004; 20100031394 and 20030056244, and U.S. Pat. Nos. 6,991,824; 7,417,178 and 7,589,252 each of which is incorporated by reference herein in its entirety.
This section will describe the various different working examples that will be used to highlight features of the present disclosure. However, the present disclosure shall in no way be considered to be limited to the particular embodiments described below.
To obtain high level expression of rhTF in rice seeds, the mature hTF protein amino acid sequence (Swiss-Prot accession number P02787, set forth as SEQ ID NO: 3) was back translated into a nucleotide sequence with the codons optimized towards the codon-usage preference of rice genes (http://www.kazusa.or.jp/codon). At the same time, internal repeats and other features that might affect mRNA stability or translation efficiency were avoided. Compared to the native gene sequence for mature hTF, nucleotides in 339 out of a total of 679 codons were modified in the codon-optimized nucleotide sequence for hTF without altering the encoded amino acid sequence, and the G+C content was increased to 65% from 50.6% in the native hTF gene sequence. To facilitate the subcloning of hTF gene into an expression vector, the MlyI blunt-cutting restriction site that allows a cut right before the first nucleotide of the hTF gene was engineered, while two consecutive stop codons followed by an XhoI restriction site were engineered after the last genetic codon of hTF gene. The entire gene sequence was synthesized by the company DNA2.0 (Menlo Park, Calif.).
The synthesized nucleotide sequence for rhTF was digested with MlyI and XhoI, and ligated in frame into the NaeI-XhoI sites of the expression vector pAPI 405; and thereby the hTF gene is operably linked to the downstream of rice seed storage protein glutelin 1 gene promoter (GU) including its signal peptide encoding sequence (GenBank accession no. Y00687) and to the upstream of the nopaline synthase (nos) gene terminator of Agrobacterium tumefaciens. The resulting plasmid was validated by sequencing in both orientations, and designated as pVB24.
The plasmid pAPI146 was used to provide a selection marker in plant transformation. The pAPI146 consists of the hpt (hygromycin B phosphor-transferase) gene encoding the hygromycin B-resistant protein under the control of rice beta-glucanase 9 gene promoter, which restricts the expression of hpt gene only in rice calli (Huang, et al., Plant Science 161: 589-95 (2001)). The linear expression cassette DNA fragments comprising the region from promoter to terminator (without the superfluous backbone plasmid sequence) (See
To identify transgenic events expressing rhTF, pooled R1 seeds of each transgenic event (R0) were analyzed because of the genetic segregation of hemizygous hTF gene in the selfed R1 seeds. Eight R1 seeds from each transgenic event were randomly picked, dehusked, and placed into eight wells in the same column of a 96 deep-well plate. Five hundred microliters of PBS buffer (pH 7.4) and two 2 mm diameter steel beads were dispensed into each well. Then, a homogeneous extract was produced by agitating the plate with a Geno/Grinder 2000 (SPEX CertiPrep, Metuchen, N.J.) for 20 min at 1300 strokes/min followed by centrifugation with a microplate centrifuge at 4,000 rpm for 20 min. Equal amounts of supernatant extract from each seed of the same transgenic event were pooled. Two microliters of the pooled protein extracts from each transgenic event were spotted onto a nitrocellulose membrane. The blot was blocked in 5% non-fat milk in Tris buffered saline tween-20 (TBST) buffer for 1 h, and then incubated with rabbit anti-hTF antibody (Abcam, Cambridge, Mass.) in TBST buffer at a concentration of 1 μg/ml for 1 h followed by washing 4 times (5 min each) with TBST buffer. Then, the blots were incubated with 1:20,000 diluted anti-rabbit HRP (horseradish peroxidase)-conjugated antibody (BioRad, Hercules, Calif.) in TBST buffer for 1 h followed by 3 washes, 5 min each in TBST buffer, and one wash in TBS buffer for 5 min. The dot blots were then incubated with the enhanced chemiluminescence (ECL) reagent (Perice Biotechnology, Rockford, Ill.) for 5 min, and then exposed to X-ray film for signal detection (See
The seed protein extracts from positive transgenic plants identified by immuno-dot blot were resolved on a 4-20% Tris-glycine SDS-PAGE gel, electro-blotted onto a 0.45 um nitrocellulose membrane for 1 h at 100V in a Bio-Rad Protean System (BioRad, Hercules, Calif.). The subsequent western blot detection procedure was the same as described for dot-immunoblot except that the secondary antibody was the anti-rabbit alkaline phosphatase-conjugated antibody (BioRad, Hercules, Calif.) at a 1:4000 dilution and that the blot was developed with BCIP/NBT substrate (Sigma, St. Louis, Mo.).
In total, 195 independent fertile transgenic rice plants (R0) were generated from the particle bombardment transformation of two rice cultivars, Bengal and Taipei 309, by using linear rhTF gene expression cassette DNA (
The transgenic events with high level expression of rhTF were identified through the denstometric analysis of the immuno dot signals followed by ELISA quantification. The expression level of rhTF in R1 seeds was shown to be about 40% of total soluble protein (TSP). However, the measurement of rhTF expression level as a percent of TSP varied significantly depending on different extraction buffers and conditions used because the extracted amount of native rice seed proteins was significantly impacted by pH, ionic strength, and temperature (data not shown). Therefore, the percent of biomass dry weight represented by rhTF is a more reliable estimate of rhTF expression level. The expression level of rhTF in some selected transgenic events was up to 8.8 mg per gram (0.088%) of dry R1 seed; and reached over 10 mg per gram (1%) of seed dry weight at R2 generation and remained stable in subsequent generation (Table 1). The relatively lower expression level of rhTF in R1 seeds compared to that in subsequent generation seeds is likely because of the poor plant growth performance and seed development of R0 plants. Similar observations have been reported by others (Hood, et al., Molecular Breeding 3 (1997) 291-306; Chikwamba, et al., Transgenic Research 11 (2002) 479-493). Data are shown in Table 1, below.
aEight R1 positive seeds from each transgenic event were assayed
bOne gram of pooled R2 seeds from a single TF-positive R1 plant was assayed
cOne gram of pooled R3 seeds from each single homozygous R2 plant was assayed
Quantification of rhTF was performed by ELISA (enzyme-linked immunosorbent assay) with a hTF ELISA assay kit (Bethyl Labs, Montgomery, Tex.) by following the manufacturer's instructions, except that the purified hTF from Sigma was used to produce the standard curve. Low expression yield of recombinant proteins has been identified as one of the major limitations of plant expression systems (Lienard, et al., Biotechnol. Annu. Rev. 13 (2007) 115-47; Fischer, et al., Curr. Opin. Plant Biol. 7 (2004) 152-8), and Farran et al. (2002) suggested that the critical limit of plant-derived recombinant protein expression level for commercial viability is 0.01% mass weight (Farran, et al., Transgenic Res. 11 (2002) 337-46). The rice-derived rhTF expression level was 100 fold higher than this suggested critical limit. This extremely high expression level will contribute to significantly reduce the production cost, and will also benefit the downstream purification.
To investigate the tissue-specificity of rhTF expression, proteins were extracted from roots, stems, leaves, leaf sheaths, anthers with pollens, grain husks, pistils, immature seeds, and mature seeds, respectively, with PBS buffer (pH 7.4), resolved on two 4-20% Tris-glycine SDS-PAGE gels (Invitrogen), run simultaneously, and stained with LabSafe Gel Blue (G Biosciences) (
Identification of the optimal extraction conditions for rhTF is important for developing a purification procedure that allows maximal protein purity and minimal purification costs. To find the optimal extraction condition for rhTF, the effect of temperature, buffer pH, ionic strength, and mixing time on protein extraction was investigated using 100 mg of rice seed flour in each treatment. The temperature effect on rhTF extraction was examined by extracting 100 mg of rice seed flour in 1 ml of PBS buffer, pH 7.4 at room temperature (RT), 37° C., 40° C., or 60° C., for 1 h. The effect of buffer pH on rhTF extractability was tested in a range from 4.5 to 10.0. The rice seed flour was extracted in each Eppendorf tube with 1 ml of 25 mM sodium acetate at pH 4.5, 5.0, 6.0; 25 mM Tris-HCl at pH 7.0, 7.5, 8.0, 9.0; or 25 mM CAPS, pH 10.0 for 1 h at RT. The ionic strength effect on rhTF extraction was determined by extracting 100 mg of rice flour in each of 1 ml 25 mM Tris-HCl, pH 8.0 with 100, 200, or 500 mM sodium chloride for 1 h at RT. The time effect on rhTF extraction was determined by extracting 100 mg of rice flour in 1 ml of 25 mM Tris-HCl, pH 8.0 for 10, 30, 60, or 120 min. After extraction, all samples were centrifuged at 13,000×g for 20 min, and the supernatants were assayed to estimate the total soluble protein (TSP) and rhTF protein content.
It was shown that while the amount of TSP increased with the increase in pH, the extracted rhTF protein was shown to increase with increase in pH from 4.5 to 7.0 but no substantial difference in the pH range of 7.0 to 10.0 (data not presented). Comparison of the effect of extraction time showed that 30 min extraction was already able to exact the maximum amount of rhTF. Neither the salt concentration nor the extraction temperature showed a significant effect on the rhTF extractability (data not shown). These results indicated that extraction of rhTF from rice flour with 25 mM Tris-HCl, pH 7.5 for 30 min at RT was the optimal condition to maximize the extraction of rhTF while minimizing the extraction of rice native proteins.
To develop a cost-effective procedure for purification of rhTF, different chromatography media and conditions were tested. The purification of rhTF protein was tested with hydrophobic interaction chromatography (HIC) medium Phenyl Sepharose 6 FF, anion exchange chromatography media Q (quaternary amine) and DEAE (diethyl amino ethane) Sepharose FF (GE, Piscataway, N.J.), respectively, using the Biologic LP chromatography system (Bio-Rad, Hercules, Calif.). Each type of chromatography media was packed to 5 cm high in a 1×10 cm Bio-Rad Econo column. The purification of rhTF protein using Phenyl Sepharose resin was carried out essentially as described in (Ali, et al., Biochem. J. 319 (Pt 1): 191-5 (1996)). For the purification of rhTF protein with anion exchange chromatography, the seed crude total proteins were extracted with 25 mM Tris-HCl buffer, pH 7.5 at a ratio of 1 to 10 of flour to buffer (g/ml) for 30 min at RT followed by centrifugation at 15,000×g for 30 min. The supernatant was filtered through a 0.2 um filter, and then loaded onto a DEAE or Q Sepharose column pre-equilibrated with 25 mM Tris-HCl buffer, pH 7.5. After the column was washed with 25 mM Tris-HCl buffer, pH 7.5 to the UV and conductivity baseline, the rhTF protein was eluted either by linear gradient from 0 to 100 mM NaCl in 25 mM Tris-HCl buffer, pH 7.5 or by a step elution with 40 mM NaCl in 25 mM Tris-HCl buffer, pH 7.5.
The HIC column with a Phenyl Sepharose was shown to be able to purify rhTF at a purity of 90%. However, a step of precipitating impure proteins with ammonium sulphate before loading onto the column could reduce the yield of rhTF and also add the purification cost. The weak anion exchange chromatography DEAE showed that the rhTF bound to the DEAE resin in the extraction buffer 25 mM Tris-HCl, pH 7.5 without the need of buffer exchange, while some rice proteins leaked out of the resin into the flow-through fractions during loading and washing. The rhTF could then be eluted from the DEAE resin with 40 mM NaCl in 25 mM Tris-HCl, pH 7.5, and was at a purity of greater than 95% based on the SDS-PAGE (
Amino (N)-Terminal Sequence Analysis.
Since a rice seed storage protein signal sequence targeting to the protein body in endosperm was fused to the N-terminus of the rhTF, N-terminal sequencing of rhTF was carried out to examine whether the rice signal sequence was cleaved correctly. Eleven sequencer cycles were analyzed, and the N-terminal sequence of rhTF was revealed as V P D K T V R W-Xc-A-V (SEQ ID NO: 23), which is identical to nhTF except that the expected cysteine amino acid residue at cycle 9 was not determined. The undetected cysteine is expected because cysteine, without special modification, cannot be detected by N-terminal sequencing. This result indicates that the rice signal sequence before the mature rhTF protein was correctly removed at the expected position.
The purified rhTF was resolved on a 4-20% Tris-glycine SDS-PAGE gel (Invitrogen, Carlsbad, Calif.) and electroblotted onto a PVDF membrane (Bio-Rad, Hercules, Calif.) in 50 mM CAPS buffer, pH 10.0. The blot was stained with 0.1% Ponceau S in 0.1% acetic acid for 5 min, and destained in 0.1% acetic acid and ddH2O. The protein band corresponding to rhTF was excised and sequenced on an ABI 494-HT Procise Edman Sequencer at the Molecular Structure Facility at the University of California, Davis, Calif., US.
Molecular Weight of rhTF.
The MALDI analysis was carried out to estimate the molecular weight of rice-derived rhTF. Three sources of TFs, rice-derived rhTF, yeast-derived aglycosylated rhTF (Millipore, Billerica, Mass.), and native hTF (Sigma, St. Louis, Mo.), were all dialyzed against 50 mM sodium acetate, 5 mM EDTA, pH 4.9 overnight followed by dialyses in ddH2O to deplete iron that was bound to TFs. These iron-free or apo-TFs were further desalted using ZipTip™μ-C18 pipette tips (Millipore, Billerica, Mass.), eluted with a solution of 70% acetonitrile (ACN), 0.2% formic acid, and 5 mg/ml MALDI matrix (α-cyano-4-hydroxycinnamic acid), and spotted onto the MALDI target and analyzed with an Applied Biosystems 4700 Proteomics Analyzer (Applied Biosystems Inc., Foster City, Calif.) at the Molecular Structure Facility at the University of California, Davis, Calif., US.
A close-up view of the MALDI spectrum of rhTF revealed a peak comprising two small split peaks on top with molecular weights of 75,255.6 and 76,573.8 Da, respectively (
Glycosylation Modifications.
To evaluate the glycosylation status of rice-derived rhTF, the purified rhTF protein was subjected to digestion with peptide-N-glycosidase F (PNGase F) (Sigma, St. Louis, Mo.). The yeast-derived aglycosylated rhTF (Millipore, Billerica, Mass.) and native hTF (Sigma, St. Louis, Mo.) were also included for comparison (
All TFs were desalted and buffer exchanged into 20 mM ammonium bicarbonate, pH 8.6 using 10 KDa MWCO Microcon spin columns (Millipore, Billerica, Mass.) with a final TF concentration of 0.5 mg/ml. Then, 45 μl of each type of TF was aliquoted into an Eppendorf tube followed by adding 5 μl of 10× denaturant (0.2% SDS, 10 mM 2-mercaptoethanol, 20 mM ammonium bicarbonate, pH 8.6) and boiling for 10 min. After the samples were cooled to RT, 5 μl of 15% Triton X-100 was added followed by the addition of 5 μl (2.5 units) PNGase F to remove the glycans from TFs. The reaction was carried out at 37° C. overnight (16 h) and analyzed by resolving 15 μl of each reaction on 4-20% Tris-glycine SDS-PAGE gel (Invitrogen, Carlsbad, Calif.) and staining with LabSafe Gel Blue (G Biosciences, St. Louis, Mo.).
As expected, the N-glycosylated nhTF showed a clear downward shift in electrophoretic mobility after PNGase F treatment, and the yeast-derived aglycosylated rhTF showed no change before and after the PNGase F treatment. Surprisingly, the electrophoretic mobility of rice-derived rhTF also remained unchanged before and after the PNGase F treatment, and its molecular size was the same as that of deglycoslated native hTF by PNGase F and yeast-derived aglycosylated rhTF. This result is consistent with the data revealed by MALDI analysis, and they all suggest that rice-derived rhTF is not N-glycosylated. The absence of N-glycosylation in rice-derived rhTF is, however, inconsistent with our prior finding in recombinant human lactoferrin (a close relative to hTF), which is expressed in rice grain using the same expression vector for rhTF and shown to be N-glycosylated (Nandi, et al., Transgenic Res. 14 (2005) 237-49; Nandi, et al., Plant Science 163 (2002) 713-22). The mechanism of the formation of non-N-glycosylated rhTF warrants further investigation.
The isoelectric point of rice-derived apo-rhTF was determined with a pre-cast Novex IEF (isoelectric focusing) gel, pH 3-10 (Invitrogen, Carlsbad, Calif.) according to manufacturer's instruction. Four micrograms of TF in dH2O were resolved at 100 V for 1 h, 200V for 1 h, and 300 V for 30 min. The native apo-hTF (Sigma, St. Louis, Mo.) and the yeast-derived aglycosylated apo-rhTF (Millipore, Billerica, Mass.) were also loaded on the gel for comparison. Lane 1=native hTF (Sigma); lane 2=yeast-derived aglycosylated rhTF (Millipore); lane 3=rice-derived rhTF. The gel was then fixed in 136 mM sulphosalicylic acid and 11.5% trichloroacetic acid (TCA) for 30 min and then stained in 0.1% Coomassie Brilliant Blue R-250 followed by destaining.
The isoelectric point (pI) of rice-derived rhTF was shown to be 6.3, which is same as the pI of yeast-derived aglycosylated rhTF but one unit higher than the pI of the native hTF (5.3) (
Conformation of rhTF The conformation and integrity of rice-derived apo-rhTF was assessed by comparing with the apo-nhTF using reverse phase liquid chromatography (RP-HPLC).
Both native apo-hTF (Sigma, St. Louis, Mo.) and rice-derived apo-rhTF were prepared in buffer A containing 0.1% trifluoroacetic acid (TFA) and 5% ACN at a concentration of 50 μg/ml and filtered through a 0.2 um syringe filter (PALL, Port Washington, N.Y.). Then 2.5 μg of each protein sample was injected to a pre-equilibrated Zorbax 3000SB-C8 column (Aglient, Santa Clara, Calif.) with buffer A using a Beckman Coulter System Gold 126 solvent module (Beckman, Fullerton, Calif.). The column was washed with three column volume of buffer A, and then run with a gradient from buffer A to 100% buffer B containing 0.04% TFA and 95% ACN in 12 column volume.
RP-HPLC resolved both the rhTF and nhTF into a major peak corresponding to their respective monomer form of the molecule, and the two peaks were shown to have the same retention time (
To test the reversible iron binding capacity of rice-derived rhTF, the purified rhTF was first dialyzed against 50 mM sodium acetate, 5 mM EDTA, pH 4.9 overnight followed by sequential dialyses in ddH2O and 25 mM Tris-HCl, pH 7.5 to remove the iron that was bound to rhTF. Then, the apo-rhTF at a concentration of 5 mg/ml in 25 mM Tris-HCl buffer, pH 7.4+10 mM NaHCO3 was titrated with increasing amount of iron (III)-nitrilotriacetate (Fe3+-NTA). The spectra were scanned from 700 to 380 nm after each addition of Fe3+-NTA, and the reading was corrected for dilution. The iron-saturated rhTF was dialyzed in 25 mM Tris-HCl buffer, pH7.5 overnight with three buffer changes to remove the unbound iron, resulting in the holo-rhTF. The iron-binding status of rhTF with different iron saturation levels was assayed by examining the mobility of rhTF on the Urea-PAGE gel with the method as described in (Evans, et al., Biochem. J. 189: 541-46 (1980); Makey, et al., Biochim. Biophys. Acta 453 250-6 (1976)). Approximately 2 μg of each TF sample was mixed with equal volume of 2× sample buffer (89 mM Tris-borate, pH 8.4, 7 M urea, 50% sucrose, 0.01% bromophenol blue), loaded onto a Novex precast 6% TBE-Urea PAGE gel (7M urea), and electrophoresed in a buffer containing 89 mM Tris-borate, 20 mM EDTA, pH 8.4 for 2 h at 170 V. The gel was stained with Coomassie blue.
The biological function of TF was measured by assessing its ability to bind and release iron reversibly. The purified, partially iron saturated (pis) rhTF from rice grains showed a salmon-pink color, a characteristic color of iron-bound TF, suggesting that rhTF has already bound iron in rice grains. After being dialyzed against 50 mM sodium acetate, 5 mM EDTA, pH 4.9 overnight followed by sequential dialysis in ddH2O and 25 mM Tris-HCl, pH 7.5, the pinkish rhTF became colorless (
To evaluate the iron binding status of purified pis-rhTF and its derived apo- and holo-isoforms after iron depletion and saturation, these rhTF samples were subjected to a urea-PAGE gel electrophoresis analysis. The apo- and holo-rhTF both showed a single band but with slower and faster electrophoretic mobility, respectively, in the urea-PAGE gel (
The electrophoretic mobility of rice-derived apo- and holo-rhTF in urea-PAGE gel was compared to that of native hTF and the yeast-derived aglycosylated rhTF (
The rice-derived rhTF was compared to the native holo-hTF (Sigma, St. Louis, Mo.) to test its effect on proliferation and productivity of hybridoma cells under serum-free conditions. The log phase Sp2/0-derived hybridoma cells AE1 (ATCC HB-72) were prepared by growing in DMEM/F12 medium+1% FBS+ITSE supplement (insulin 10 μg/ml, TF 5.5 μg/ml, Sodium selenite 0.0067 μg/ml, ethanolamine 2.0 μg/ml (Invitrogen, Carlsbad, Calif.). The cells were then washed three times with DMEM/F12 without supplements to remove FBS and TF, and seeded in serum-free assay medium (DMEM/F12 supplemented with ISE (no TF) and 1 g/L CELLASTIM™ (recombinant human albumin) (InVitria, Fort Collins, Colo.)) at 0.8×105 viable cells/ml. A dose response study was carried out by adding rhTF or its native counterpart hTF (Sigma, St. Louis, Mo.) into assay medium at concentrations of 0.03, 0.1, 0.3, 1.0, 5.0, and 30 μg/ml and examining their cell proliferation effect after three days of growth in a humidified incubator, 37° C., 6% CO2. The negative control was the same assay medium without any added TF, while 10% FBS and ITSE cocktail (Invitrogen, Carlsbad, Calif.) in assay medium were positive controls. The assay was carried out in duplicate 1 ml stationary cultures for each condition. The concentration of viable cells was determined by a Guava PCA cell counter. The cell proliferation effect of rhTF was further evaluated by using cell growth curve. The AE1 cells were grown in assay medium with the addition of rhTF or native hTF at 10 μg/ml, and the concentration of viable cells was determined every day for six days.
The cell productivity of rhTF was assayed by quantifying the amount of antibody produced in hybridoma cells at day 6 through ELISA. After cells and debris were removed from the media by centrifugation, the antibody quantity was measured using by ELISA as instructed by the manufacturer (Bethyl Labs, Montgomery, Tex.).
Effect of rhTF on Cell Growth and Antibody Production
Rice-derived pis-rhTF was shown to have an equivalent dose response as native holo-hTF for the proliferation of hybridoma cells (
While various specific embodiments have been illustrated and described in some detail for purposes of clarity of understanding, it will be appreciated by those of ordinary skill in the art in light of these teaching that various changes can be made without departing from the spirit and scope of the claims. Therefore, it is to be understood that the disclosure is not to be limited to the specific embodiments disclosed herein, as such are presented by way of example. It will also be apparent to those of ordinary skill in the art that each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope and spirit of the teachings. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.
All literature and similar materials cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, internet web pages and other publications cited in the present disclosure, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety for any purpose to the same extent as if each were individually indicated to be incorporated by reference. In the event that one or more of the incorporated literature and similar materials differs from or contradicts the present disclosure, including, but not limited to defined terms, term usage, described techniques, or the like, the present disclosure controls.
This application is a continuation of U.S. patent application Ser. No. 13/102,966, filed 6 May 2011 and published as US 20120088729; and pursuant to 35 U.S.C. §119 (e), to the filing date of U.S. Provisional Patent Application Ser. No. 61/332,733 filed 7 May 2010, the disclosures of each of which are herein incorporated by reference in their entirety.
This work was supported in part with government support under NIH grant GM086916 from the National Institute of General Medical Sciences. The United States government may have rights to certain aspects of the disclosure.
| Number | Date | Country | |
|---|---|---|---|
| 61332733 | May 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13102966 | May 2011 | US |
| Child | 14668955 | US |
